Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Lyell Immunopharma (LYEL) EBT Margin (2020 - 2025)

Historic EBT Margin for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to 226580.0%.

  • Lyell Immunopharma's EBT Margin fell 955800000.0% to 226580.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 798982.93%, marking a year-over-year decrease of 4959924500.0%. This contributed to the annual value of 548667.21% for FY2024, which is 3767018300.0% down from last year.
  • Lyell Immunopharma's EBT Margin amounted to 226580.0% in Q3 2025, which was down 955800000.0% from 548300.0% recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's EBT Margin ranged from a high of 23.42% in Q4 2022 and a low of 2139533.33% during Q3 2022
  • Moreover, its 5-year median value for EBT Margin was 209724.0% (2023), whereas its average is 448089.51%.
  • As far as peak fluctuations go, Lyell Immunopharma's EBT Margin tumbled by 2000000000bps in 2022, and later skyrocketed by 2000000000bps in 2023.
  • Over the past 5 years, Lyell Immunopharma's EBT Margin (Quarter) stood at 1673.1% in 2021, then skyrocketed by 99bps to 23.42% in 2022, then crashed by -1721920bps to 403261.54% in 2023, then tumbled by -342bps to 1783881.82% in 2024, then surged by 87bps to 226580.0% in 2025.
  • Its EBT Margin was 226580.0% in Q3 2025, compared to 548300.0% in Q2 2025 and 764357.14% in Q1 2025.